Evaluation of Efficacy and Safety of Ciprofloxacin Ophthalmic Solution versus Chloramphenicol

The results of this clinical study demonstrate that ciprofloxacin ophthalmic solution 0.3% is as safe and as effective as 0.5% chloramphenicol ophthalmic solution in the treatment of conjunctivitis and blepharitis of bacterial aetiology. Both agents achieved microbiological improvement rates in excess of 90% after 1 week's treatment. On ciprofloxacin 93.5% of patients were judged clinically cured or improved versus 84.6% on chloramphenicol after 1 week. There were no serious adverse affects. One patient in each group suffered drug-related side-effects (chemosis, erythema) which resolved on discontinuation or changing of therapy. Cirpofloxacin is not associated with the rare, but serious, side effect of aplastic anaemia which is associated with chloramphenicol use. On the evidence of this study ciprofloxacin would appear to be an appropriate agent for general use as a topical ophthalmic formulation.

Download Full-text

Correction to: Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.3% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial, by Baiza-Durán, L., Olvera-Montaño, O., Mercado-Sesma, A.R., and Oregon-Miranda, A.A. J Ocul Pharmacol Ther 2018;34(3):250-255. DOI: 10.1089/jop.2017.0056

Journal of Ocular Pharmacology and Therapeutics ◽

10.1089/jop.2017.0056.correx ◽

2019 ◽

Vol 35 (1) ◽

pp. 76-76

Keyword(s):

Clinical Trial ◽

Randomized Clinical Trial ◽

Ophthalmic Solution ◽

Efficacy And Safety ◽

Bacterial Conjunctivitis ◽

Solution Versus

Download Full-text

Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.3% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial

Journal of Ocular Pharmacology and Therapeutics ◽

10.1089/jop.2017.0056 ◽

2018 ◽

Vol 34 (3) ◽

pp. 250-255 ◽

Cited By ~ 2

Author(s):

Leopoldo Baiza-Durán ◽

Oscar Olvera-Montaño ◽

Arieh R. Mercado-Sesma ◽

Aldo A. Oregon-Miranda ◽

Alfredo Lizárraga-Corona ◽

...

Keyword(s):

Clinical Trial ◽

Randomized Clinical Trial ◽

Ophthalmic Solution ◽

Efficacy And Safety ◽

Bacterial Conjunctivitis ◽

Solution Versus

Download Full-text

Efficacy and safety results of pemetrexed administration in non-small cell lung cancers, a multicenter study of the Association of Anatolian Medical Oncology.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.e19107 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. e19107-e19107

Author(s):

Nurgul Yasar ◽

Olcun Umit Unal ◽

Caglayan Geredeli ◽

Ali Inal ◽

Veli Berk ◽

...

Keyword(s):

Side Effects ◽

Disease Control ◽

Side Effect ◽

Performance Status ◽

Combined Treatment ◽

Single Agent ◽

Prognostic Significance ◽

Platinum Resistance ◽

Second Line ◽

Efficacy And Safety

e19107 Background: In this study, the efficacy and safety of pemetrexed chemotherapy was evaluated retrospectively in patients who were non-responders to or who have demonstrated progression after the first and/or second line treatments in local advanced and metastatic NSCLC. Methods: 175 patients (139 males, 36 females) were assessed in years 2008 – 2012. Patients were given pemetrexed 500 mg/m2, and the ones receiving combined treatment were given pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 once in every 21 days. Supplementary steroid and vitamin treatment were administered to all patients. Age, gender, performance status (PS), stage, single agent or combined administration of treatment, progression-free survival (PFS) and overall (OS) were investigated. Patients were assessed in terms of treatment efficacy and toxicity. Results: Median follow-up period was 6 months (1 - 25), and median age was 55 years (28 - 83). In 82% of patients, PS was 0 – 1. 73% of patients were at stage 4. 71% of the patients received single agent pemetrexed, and 14% received platinum - pemetrexed combination treatment. 93% of patients received pemetrexed treatment as second line. Median 3 cycles of treatment (1 – 12) were administered. In side effect assessment, while side effects (grade 1 – 4) were observed in 62% of the patients, the most frequently observed side effects were anemia (18%) and nausea-vomiting (15%). Febrile neutropenia was detected in 6 patients (3.4%).In assessment of the response, the disease control ratio was 50% (21% partial response, 29% stable disease). 1- and OS rates were respectively 14% and 41%. Median OS was 10 months (SE:1, 95% CI: 7-12) and median PFS was 3 months (SE:1, 95% CI: 2-4). In multivariate analysis, PS of 0 – 1 and response to treatment were found as factors with prognostic significance (p=0.047, p=0.014, respectively). Conclusions: It is observed that chemotherapy regimen containing pemetrexed in NSCLC treatment is a treatment approach, which provides an efficient disease control with a manageable side effect profile, in patients especially with good performance status and with no platinum resistance, who can receive treatment in combination form.

Download Full-text

Effect of oral misoprostol, alone or in combination with aglepristone, on mid-term pregnancy termination in cats

Journal of Feline Medicine and Surgery ◽

10.1177/1098612x18797139 ◽

2018 ◽

Vol 21 (8) ◽

pp. 714-722

Author(s):

Serhan Serhat Ay ◽

Selim Aslan ◽

Firdevs Önyay ◽

Duygu Kaya ◽

Ece Koldaş ◽

...

Keyword(s):

Side Effects ◽

Side Effect ◽

Pregnancy Termination ◽

Low Doses ◽

Efficacy And Safety ◽

Term Pregnancy ◽

Blood Samples ◽

Oral Misoprostol ◽

Higher Doses

Objectives This study aimed to determine the efficacy and safety of oral misoprostol (MIS) administration in the induction of mid-term pregnancy termination in cats. Methods Twenty-eight cats that were pregnant for 30–40 days were allocated to four groups. The aglepristone (AGL) group (n = 7) received 10 mg/kg SC aglepristone q24h for two consecutive days. In the AGL+MIS group (n = 7), AGL (as administered in the AGL group) and MIS (200 µg/cat PO q12h until the start of abortion) were administered. The MIS200 (n = 7) and MIS400 groups (n = 7) received MIS (200 or 400 µg/cat misoprostol, respectively) alone PO q12h until the start of abortion. Blood samples were collected at the start of treatment (d0), 4 days after the start of treatment (d4) and on the day of complete abortion/end of administration (dA/d7). Results The efficacy of the treatment was 71.4% in the AGL group, 100% in the AGL+MIS group, 0% in MIS200 group and 57.4% in MIS400 group ( P = 0.004). No significance was found in relation to the interval from treatment to the start/end of abortion and the duration of abortion in all groups. The most observed side effect was vomiting in both groups administered MIS, particularly in the MIS400 group (56.7%). Progesterone (P4) concentrations were reduced during the abortion, but not to basal levels, in all groups. P4 concentrations were significantly lower at dA/d7 in the MIS400 group compared with the AGL and AGL+MIS groups ( P = 0.002). Conclusions and relevance The results obtained from this study showed that low doses of MIS do not induce abortions in cats but increase the effect of AGL. Although higher doses could terminate pregnancies, this also causes intense unwanted side effects. Therefore, the use of MIS alone as an abortifacient in cats is not recommended. For mid-term pregnancy termination in cats, the combination of misoprostol and aglepristone provides a more effective abortifacient than using either of them alone.

Download Full-text

Efficacy and safety of the PRO-087 Ophthalmic solution versus systane(R) Ultra and Systane(R) Ultra Preservative-free on the tear film dysfunction syndrome from mild to moderate. v1 (protocols.io.3wvgpe6)

protocols.io ◽

10.17504/protocols.io.3wvgpe6 ◽

2019 ◽

Author(s):

Sandra Belalc ◽

Valeria S ◽

Juan C ◽

Samuel Altamirano ◽

Abraham Soto ◽

...

Keyword(s):

Tear Film ◽

Ophthalmic Solution ◽

Efficacy And Safety ◽

Solution Versus ◽

Preservative Free

Download Full-text

Cutaneous ulcers following hydroxyurea therapy

Phlebologie ◽

10.1055/s-0037-1621559 ◽

2004 ◽

Vol 33 (06) ◽

pp. 202-205 ◽

Cited By ~ 2

Author(s):

K. Hartmann ◽

S. Nagel ◽

T. Erichsen ◽

E. Rabe ◽

K. H. Grips ◽

...

Keyword(s):

Side Effects ◽

Side Effect ◽

Antineoplastic Agent ◽

Limited Time ◽

Myeloproliferative Diseases ◽

Dermatological Side Effects ◽

Chronic Myeloproliferative Diseases ◽

Hydroxyurea Therapy

SummaryHydroxyurea (HU) is usually a well tolerated antineoplastic agent and is commonly used in the treatment of chronic myeloproliferative diseases. Dermatological side effects are frequently seen in patients receiving longterm HU therapy. Cutaneous ulcers have been reported occasionally.We report on four patients with cutaneous ulcers whilst on long-term hydroxyurea therapy for myeloproliferative diseases. In all patients we were able to reduce the dose, or stop HU altogether and their ulcers markedly improved. Our observations suggest that cutaneous ulcers should be considered as possible side effect of long-term HU therapy and healing of the ulcers can be achieved not only by cessation of the HU treatment, but also by reducing the dose of hydroxyurea for a limited time.

Download Full-text